1. Home
  2. Directory
  3. Maine
  4. Scarborough
  5. Obstetrics Gynecology
  6. NPI Profile
  7. Prescriptions 1124063441

LESLIE SIRIYA BRADFORD MD
Prescription History 1124063441
Obstetrics & Gynecology - Gynecologic Oncology in Scarborough, ME


Quality Rating: 98.06 out of 100 score

NPI Status: Active since June 19, 2006

Contact Information

100 CAMPUS DR STE 125
SCARBOROUGH, ME
ZIP 04074
Phone: (207) 883-0069

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for LESLIE SIRIYA BRADFORD MD, an active Gynecologic Oncology specialist practicing in Scarborough, ME. Our medical registry currently tracks 4 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 107 documented patient claims. Among these therapy options, the most frequently utilized medication is Prochlorperazine Maleate, which accounts for 36 claims alone.

Medication Index

D
G
O
P
No matching medications currently found on file.

Dexamethasone

Generic Formulation: DexamethasoneSpecialty: Gynecological Oncology
Provider Metrics Summary
Total Claims 27
30-Day Fills 27.0
Days Supply 331
ME State Average Benchmarks
Peer Average Claims26.0
Peer Average 30-Day Fills29.7
Peer Average Days Supply518
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across ME. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $422.02 across this reporting matrix range.

Provider Avg Cost Per Claim

$15.63

State Avg Cost Per Claim

$20.45

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

An anti-inflammatory 9-fluoro-glucocorticoid.

Therapeutic Applications

Dexamethasone is used to treat conditions such as arthritis, blood/hormone disorders, allergic reactions, skin diseases, eye problems, breathing problems, bowel disorders, cancer, and immune system disorders. It is also used as a test for an adrenal gland disorder (Cushing's syndrome). Dexamethasone belongs to a class of drugs known as corticosteroids. It decreases your immune system's response to various diseases to reduce symptoms such as swelling and allergic-type reactions.

Gabapentin

Generic Formulation: GabapentinSpecialty: Gynecological Oncology
Provider Metrics Summary
Total Claims 15
30-Day Fills 15.0
Days Supply 360
ME State Average Benchmarks
Peer Average Claims67.0
Peer Average 30-Day Fills119.3
Peer Average Days Supply3,480
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 77.6% less volume than the regional standard for practitioners inside ME. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $128.76 across this reporting matrix range.

Provider Avg Cost Per Claim

$8.58

State Avg Cost Per Claim

$30.35

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A cyclohexane-gamma-aminobutyric acid derivative that is used for the treatment of PARTIAL SEIZURES; NEURALGIA; and RESTLESS LEGS SYNDROME.

Therapeutic Applications

Gabapentin is used with other medications to prevent and control seizures. It is also used to relieve nerve pain following shingles (a painful rash due to herpes zoster infection) in adults. Gabapentin is known as an anticonvulsant or antiepileptic drug.

Ondansetron Hcl

Generic Formulation: Ondansetron HclSpecialty: Gynecological Oncology
Provider Metrics Summary
Total Claims 29
30-Day Fills 29.0
Days Supply 152
ME State Average Benchmarks
Peer Average Claims24.0
Peer Average 30-Day Fills24.0
Peer Average Days Supply64
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across ME. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $197.57 across this reporting matrix range.

Provider Avg Cost Per Claim

$6.81

State Avg Cost Per Claim

$8.41

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used alone or with other medications to prevent nausea and vomiting caused by cancer drug treatment (chemotherapy) and radiation therapy. It is also used to prevent and treat nausea and vomiting after surgery. It works by blocking one of the body's natural substances (serotonin) that causes vomiting.

Prochlorperazine Maleate

Generic Formulation: Prochlorperazine MaleateSpecialty: Gynecological Oncology
Provider Metrics Summary
Total Claims 36
30-Day Fills 37.5
Days Supply 332
ME State Average Benchmarks
Peer Average Claims28.0
Peer Average 30-Day Fills28.9
Peer Average Days Supply377
Elevated Utilization

This provider maintains an active emphasis on this therapeutic option, recording 28.6% more claims than the standard regional baseline profile for ME. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $406.83 across this reporting matrix range.

Provider Avg Cost Per Claim

$11.30

State Avg Cost Per Claim

$17.17

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A phenothiazine antipsychotic used principally in the treatment of NAUSEA; VOMITING; and VERTIGO. It is more likely than CHLORPROMAZINE to cause EXTRAPYRAMIDAL DISORDERS. (From Martindale, The Extra Pharmacopoeia, 30th ed, p612)

Therapeutic Applications

This medication is used to treat severe nausea and vomiting from certain causes (for example, after surgery or cancer treatment). Prochlorperazine belongs to a class of drugs known as phenothiazines. This medication is not recommended for use in children younger than 2 years or in children going through surgery.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like LESLIE SIRIYA BRADFORD MD provides transparency into local medical care patterns within Scarborough, ME.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Gynecologic Oncology** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.